An analog is a peptide deliberately altered from a reference molecule while retaining enough of its structure to act at the same target. Four modification types cover most cases: residue substitution, including non-natural amino acids such as Aib; terminal capping by acetylation or amidation; truncation or extension; and conjugation of a fatty acid, PEG chain or DAC linker.
Why analogs matter in peptide research
Almost every peptide of commercial or research interest is one. Semaglutide is a GLP-1 analog with an Aib substitution at position 8 that blocks DPP-4 cleavage plus a C18 di-acid for albumin binding, taking a two-minute half-life to roughly a week. IGF-1 LR3 substitutes one residue and extends the chain to reduce binding-protein capture. In each case a small structural change produces a large behavioural one.
That is precisely why analog data does not transfer. An analog and its native sequence parent differ in clearance, receptor selectivity and often in off-target profile, so findings for one are not evidence for the other — and human trial data existing for an approved analog says nothing about an unstudied research-grade relative. Compare fragments; see why the IGF modifications exist.